Dimerix Limited · ASX:DXB
Dimerix — Euroz Hartleys Institutional Conference 2026
26 slides from Dimerix's conference presentation, Mar 19, 2026
Slide 1: Euroz Hartleys Institutional Conference
(ASX:DXB) Developing new therapies to treat inflammatory causes of kidney disease with unmet clinical needs Euroz Hartleys Institutional Conference Rottnest Island – 17-19 March 2026 Authorised for lodgement by the Board of the Company
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will
Slide 3: Overview: Phase 3 Global Opportunity
Overview Phase 3 Global Opportunity Phase 3 trial Reduced risk FSGS indication No approved Orphan drug 4 commercial up to $1.4 billion recruitment Proteinuria endpoint is a rare disease treatments designations partners in total complete in passed blinded that causes scarring specifically for regulat
Slide 4: Cycle of damage in glomerular diseases
Cycle of damage : in glomerular diseases Existing blood pressure medication What is FSGS? Glomeruli exposed to stress from high blood pressure DMX-200 Focal = some 1 Segmental = sections High blood pressure causes hyperfiltration within filter units Glomerulo = of the kidney filtering units (glomeru
Slide 5: Interpreting proteinuria as a surrogate endpoint
Interpreting proteinuria as a surrogate endpoint Proteinuria is the quantity of protein in the urine Proteinuria as a predictor of kidney disease3 A healthy kidney is a good filter and allows little to no protein into Dip test uPCR g/g the urine1 NORMAL Neg <0.13 normal Inside a healthy kidney Insid
Slide 6: Measuring eGFR as a surrogate endpoint
Measuring eGFR as a surrogate endpoint Estimated glomerular filtration rate (eGFR) is the measurement of the kidney filtration rate Treatments, such as DMX-200, aim to bring the FSGS slope back up: • can add years to the life of the kidney • potential to delay dialysis and/or kidney transplant • Kid
Slide 7: DMX-200 – inflammatory modulator
DMX-200 – inflammatory modulator A CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR) Commercial manufacturing sites established in USA3 1. ASX release and investor presentation 29Jul20 and ASX release 11Mar24 BID: bis in d
Slide 8: DMX-200: Phase 2 met primary endpoint
DMX-200: Phase 2 met primary endpoint Clinically encouraging outcomes achieved for patients,1,2 with no safety concerns noted3 Average reduction of 17% in proteinuria after 16 weeks treatment on DMX-200 versus placebo3 “Any reduction in proteinuria could yield years of preserved native kidney EFFICA
Slide 9: Phase 3 clinical trial
European Renal Association Posters 2025 phase 3 clinical trial A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB (n=≥286) Background Phase 3 Trial Timeline Open Label Extension Successful interim analysis1 Planned b
Slide 10: Adult patient recruitment by territory
Adult patient recruitment by territory Trial designed for potential Recruitment approval globally completed (adult population)1 333 Adult patients recruited, randomised and dosed (target ≥286)2 6 Paediatric patients recruited, randomised and dosed2 Latin America Asia Pacific US / Europe 1. ASX relea
Slide 11: Evolution of FSGS landscape & ACTION3 study
Evolution of FSGS landscape & ACTION3 study Oct 2023: Partnered with Advanz for UK, EU, Sep 2024: First ACTION3 patient Canada and ANZ completes 2 years and enters May 2025: partnered with Open Label Extension Study Amicus for USA Dec 2025: n = 286 adults Nov 2023: IND randomised and dosed June 2024
Slide 12: Next steps
next steps PARASOL working group conducted “ACTION3-like” population analysis of larger PARASOL observation dataset1 • Results of this analysis are generally consistent with the broader PARASOL analysis conducted in 2024 • Potential relationship between proteinuria at 12 months and subsequent risk o
Slide 13: Competitive/complementary landscape in FSGS
Competitive/complementary landscape in FSGS Low competition in inflammatory treatment options, large unmet medical need DMX-200 is the only inflammatory modulator in development DMX-200 has potential for use in conjunction with other drugs in development if approved AT-1 / ETA antagonist Preclinical
Slide 14: Rare kidney disease – a potential growth market
Rare kidney disease – a potential growth market Biopsy 7 per 1,000,000 FSGS is the most DMX-200 frequent primary FSGS diagnosis driven by glomerular disease Commercial rates of biopsy - growth Global incidence rate of that reaches end-stage manufacturing sites potential as biopsy rates FSGS per capi
Slide 15: Summary of licensing deals for DMX-200 to date
Summary of licensing deals for DMX-200 to date Licensing deals collectively Dimerix has successfully partnered DMX-200 across key markets valued up to 1 2 3 4 ~AU$1.4 billion in total upfront and potential milestone fees plus royalties1 United States EU, CA, AU, NZ GCC, Iraq Japan AU$48 AU$10.8 AU$0
Slide 16: DMX-200 substantially de-risked Phase 3 renal asset
DMX-200 substantially de-risked Phase 3 renal asset ACTION3 primary Proteinuria endpoint Commercial Study fully recruited: endpoint: proteinuria reduced risk: passed validation: 4 fixed timelines to full has potential for blinded interim commercial partners study completion in stronger statistical (
Slide 17: Growth strategy
Growth strategy Deliver ACTION3 Phase 3 Expand global commercial Advance pipeline development clinical trial partnerships • Identify and progress new assets in • Ensure drug supply continuity and • Build on existing licensing agreements renal and/or rare disease indications patient visits for recrui
Slide 18: Corporate overview
Corporate overview S H A R E P R I C E Ticker Symbol ASX: DXB Cash Balance (Dec25) $38.5 million Market Capitalisation1 $220 million Share price1 $0.35 Total ordinary shares on issue1 600,396,776 Average Daily Liquidity by value for $0.65 million past 30 trading days2 Research Coverage Analyst S UBS
Slide 19: Well positioned to deliver against strategic plan
(ASX:DXB) W E L L P O S I T I O N E D TO D E L I V E R AGA I N ST ST R AT EG I C P L A N ESG Statement Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to
Slide 20: DMX-200: unique pharmacology
DMX-200: unique pharmacology • CCR2 activation promotes recruitment of inflammatory 500 Proteinuria (mg/24hours) monocytes to the kidney 400 300 DMX-200 inhibits CCR21 200 Simultaneous inhibition of * CCR2 and AT1R reduces 100 proteinuria an important • Monocytes promote sclerosis and fibrosis of th
Slide 21: DMX-200 Phase 2 effect on inflammatory biomarker
DMX-200 Phase 2 effect on inflammatory biomarker1 Unlike other CCR2 antagonists investigated to date, treatment with DMX-200 reduces the urine concentration of the pro-inflammatory ligand of CCR2 called MCP-12 Average baseline MCP-1 versus Change in MCP-1 over time on average baseline proteinuria DM
Slide 22: PARASOL: proteinuria as an endpoint for full FDA approval
PARASOL: proteinuria as an endpoint for full FDA approval 1 2 PARASOL FSGS Working Group 2024 Biological Plausibility ➢ PARASOL was formed in Dec-23 to address the need to validate alternative ➢ The FDA has emphasised the need for programs wishing to use proteinuria surrogate endpoints for FSGS, and
Slide 23: Intellectual property portfolio
Intellectual property portfolio DMX-200 Exclusivity Portfolio 3 7/10 years Exp.2042 Orphan exclusivity from (if granted) marketing approval date in many territories1 Portfolio 2 Formulation Portfolio 5 Global application3 + Exp.2042 Exp.2045/6 (if granted) Paediatric (if granted) exclusivity period
Slide 24: Dimerix board
Dimerix board Previous experience: Previous experience: Previous experience: Previous experience: Previous experience: (2) (1) (Faulding)(1) • Senior pharmaceutical executive • Experienced in product • Extensive biotech drug • Experienced executive in • Experienced technology and with a demonstrated
Slide 25: Dimerix management
Dimerix management Previous experience: Previous experience: Previous experience: Previous experience: (1) • Experienced in product • Experienced finance and • 35 years international experience • Experienced pharmaceutical development, commercial strategy governance executive with in drug developmen
Slide 26: Medical Advisory Board
Medical Advisory Board Professor of Clinical Trials and Professor of Medicine & Mayer Professor of Renal An attending physician and Renal Physician and Head of Graduated from Haverford Assistant Professor in the Personalized Medicine: Molecular & Cellular Medicine: Department of Director of the Kidn
Dimerix — Euroz Hartleys Institutional Conference 2026 on 6ix